Higher plasma myeloperoxidase levels are not associated with an increased risk for cardiovascular events in HIV-infected adults

HIV Clinical Trials

Volumn 9, Issue 3, 2008, Pages 207-211

  El Bejjani, Dalia ^a   Hazen, Stanley L ^b   Mackay, Wilma ^c   Glass, Nina E ^d   Hulgan, Todd ^d   Tungsiripat, Marisa ^b   McComsey, Grace A ^a,c,e  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Biomarkers; Cardiovascular disease; Myeloperoxidase; Myocardial infarction

Indexed keywords

CHOLESTEROL; MYELOPEROXIDASE; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PEROXIDASE; RISK FACTORS;

EID: 45949101837     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0903-207     Document Type: Article

References (13)

1. The DAD Writing Committee. Cardio- and cerebrovascular events in HIV-infected persons. AIDS. 2004;18:1811-1817.
2. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109(13): 1603-1608.
3. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. New Engl J Med. 2007; 356(17):1723-1735.
4. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
5. Hruz PW, Murata H, Mueckler M. Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism. Am J Physiol Endocrinol Metab. 2001;280(4):E549-E553.
6. Shishehbor MH, Hazen SL. Inflammatory and oxidative markers in atherosclerosis: relationship to outcome. Curr Atheroscler Rep. 2004;6(3):243-250.
7. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136-2142.
8. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595-1604.
9. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440-1445.
10. Vita JA, Brennan ML, Gokce N, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004; 110(9): 1134-1139.
11. Phillips A, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman W, et at. Interruption of ART and risk of cardiovascular disease: findings from SMART. In: Program and abstracts from the 14th Conference on Retroviruses and Opportunistic Infections; February 2007; Los Angeles. Abstract 41.
12. Torriani FJ, Komarow L, Cotter BR, Murphy RL, Fichtenbaum CJ, Currier JS, et al. Control of HIV viral replication is associated with rapid improvement in endothelial function sustained over 24 weeks: A5152s, a substudy of A5142. Antiviral Ther. 2007;12(Suppl 2):L15.
13. Ross A, Armentrout R, O'Riordan M, Storer N, Rizk N, Harrill D, et al. Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy (ART) and lipoatrophy. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 2008; Boston, MA.